Research Methodology · Short notes

Clinical Trial Phases: Short Notes & Cheat Sheet

Preclinical work, phases 0 to IV with their aims and sizes, GCP roles, safety reporting and trial approval in Pakistan.

Short notes

Read these before you attempt the topic's MCQs.

Numbers grow at each phase; most candidates fail in phase II, where efficacy is first tested properly.

Preclinical studies (laboratory and animal) establish pharmacology, toxicology and ADME before human use.
Phase 0 (optional): microdoses in about 10–15 people to study pharmacokinetics; no therapeutic effect expected.
Phase I: first in humans, usually 20–100 healthy volunteers (patients for cytotoxic drugs). It studies safety, tolerability, pharmacokinetics and the maximum tolerated dose, using dose escalation.
Phase II: about 100–300 patients. It tests efficacy and finds the best dose (IIa proof of concept, IIb dose-ranging).
Phase III: hundreds to thousands of patients in multicentre randomised trials, confirming efficacy and safety against placebo or standard care. These pivotal trials support the marketing application.
Phase IV: after approval. Post-marketing surveillance finds rare and long-term reactions and studies new populations and uses.

GCP (ICH E6) protects participants' rights and safety and ensures reliable data.
Roles: the sponsor funds and runs the trial, the investigator conducts it at a site, monitors check data, a contract research organisation may act for the sponsor, and an independent data safety monitoring board reviews accumulating safety data.
Every participant gives informed consent, and an ethics committee approves the protocol.
Investigators report serious adverse events to the sponsor quickly (typically within 24 hours). Suspected unexpected serious adverse reactions (SUSARs) are reported to regulators on expedited timelines.

Developing a new drug usually takes 10–15 years, and only about 1 in 10 drugs entering phase I is approved.
Trials should be registered in a public registry before recruitment begins.
In Pakistan, clinical trials need approval from DRAP and ethical approval from a recognised ethics committee, such as the National Bioethics Committee.

High-yield facts in one place. Cover the right-hand column and test yourself.

Phase	Who · main aim
0	≈ 10–15 people · microdose PK
I	20–100 healthy volunteers · safety, PK, dose
II	100–300 patients · efficacy, dose-finding
III	Hundreds–thousands of patients · confirm efficacy and safety
IV	General population · post-marketing surveillance

Role	Responsibility
Sponsor	Initiates, funds and manages the trial
Investigator	Conducts the trial at the site
Monitor (CRA)	Checks data and GCP compliance
Ethics committee	Approves and oversees ethics
DSMB	Independent review of safety data

I Safe, II Works?, III Better?, IV Real world: Phase I tests safety, II efficacy, III comparison, IV post-marketing experience.

Phase I trials of cytotoxic drugs use patients, not healthy volunteers.
Phase IV happens after the drug is approved and marketed.
Phase III, not phase II, provides the pivotal evidence for approval.
Rare adverse reactions usually appear only in phase IV, because earlier trials are too small.

Attempt the Clinical Trial Phases MCQs while the notes are fresh. Anything you get wrong is saved to your incorrect list for the next revision round.